Bryan Hughes is a Managing Director of PMCF and leads the firm’s Healthcare team. In addition to leading this team, he also assists the firms’ transactional needs within the business services & technology and consumer, food, & retail sectors. He has more than 20 years of industry experience advising clients with mergers and acquisitions, leveraged buyouts, private placements, financings, valuation, and strategic consulting. From large global companies to small, privately-held businesses, Bryan’s clients include contract manufacturers, life sciences companies, diagnostics businesses, drug delivery services, laboratories, and medical device manufacturers. He has completed over 30 transactions with a combined deal value totaling more than $5 billion.
Bryan began his career at PMCF as an Analyst. Over his tenure at the firm, he was promoted several times, advancing to his current role as Managing Director. Bryan has written numerous articles for healthcare and medical technology industry publications. He is a frequent speaker at business, media, and industry organization events, sharing his insight of various investment banking topics, such as M&A and macro trends within the medical manufacturing and healthcare industries.
Bryan earned a BBA with an emphasis in finance from the Stephen M. Ross School of Business at the University of Michigan. He is a licensed securities representative holding his Series 7 and 63 registrations.
Transactions
has been acquired by
a portfolio company of
has been acquired by
has been acquired by
a portfolio company of
a portfolio company of
has been acquired by
has been acquired by
a portfolio company of
a business unit of
has been acquired by
a portfolio company of
has acquired certain assets of
has sold
to
have been acquired by
has been acquired by
has acquired
has acquired
completed the private placement of $30,500,000 convertible preferred equity with Pharos Capital Group, LLC, Highlander Partners, LP, Hopewell Ventures, and River Cities Capital Funds
has divested its
implant product line to
a Healthpoint Capital Company
has licensed its corplex technology for certain applications to
has acquired a majority equity interest in
has acquired microneedle technology from
has acquired the medical product business of
and
have been acquired by
has sold an equity interest to
has acquired
Featured Articles
- August 30, 2022
- | Industry Updates
- | Healthcare, Medical Technology
- February 28, 2022
- | Industry Updates
- | Medical Technology
- November 30, 2021
- | Industry Updates
- | Healthcare, Medical Technology
